stimOS GmbH, a Constance, Germany-based medical technology company, raised a a Series A funding round of undisclosed amount.
WEFA Inotec GmbH, a German market leader in extrusion tooling, precision technology and CVD coatings, participated in the round, along with HTGF, MBG and founding partner Dietmar Schaffarczyk, who are increasing their shares.
The investment will be used to turn the patented “Mimicking Bone Technology (MBT)” into an internationally industrial benchmark and to establish the technology as the golden standard for osseointegrative implant surfaces.
stimOS has developed MBT, a biochemical process that initiates the formation of healthy bone, has anti-inflammatory effects, provides acute anchoring of the implants and improves healing substantially. Instead of relying on existing coating technologies, the company restructures implant materials in a biochemical way by using a covalently bonded activation layer: MBT imparts cell-biological properties onto inert materials, as known from nature and naturally occurring in the patient’s body. The MBT process is currently being adapted for high volumes in order to ensure comprehensive patient care.